

## EDITORIAL

## Accounting for diversity in rare disease research and precision medicine



We live in an age where the concept of precision medicine is no longer aspirational but is now institutionalized, not only being used in clinical practice but also helping to drive novel research. The National Institutes of Health (NIH) defines precision medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle of each person.”<sup>1</sup>

Tabor and Goldenberg,<sup>2</sup> authors of a recent publication in the *American Medical Association Journal of Ethics*, addressed potential concerns regarding how the increasing use of precision medicine may ultimately create new subcategories of patients based on the relative population frequencies of their genomic variances. The authors suggested that research initiatives and novel therapies are likely to be designed primarily for individuals who have more frequently occurring genetic variances, thereby creating treatment challenges and health outcome disparities for patients who are diagnosed with “common” diseases but have rare genetic variances associated with them. Tabor and Goldenberg further opined how the evolution of precision medicine can be shaped by lessons learned from those invested in the care and research of persons with rare diseases.<sup>2</sup>

Several million people live with diseases that are so unusual and rare that they may often go years without obtaining an accurate diagnosis. In contrast, there are other rare diseases that are well recognized, yet there has been only limited understanding of their pathogenesis and/or limited efforts made toward the development of targeted therapies. Because of the rarity of these diseases, it remains a challenge long-recognized by clinicians, scientists, and patient advocacy groups to convince governmental agencies and companies to provide the resources needed to study them and to develop effective and affordable therapies. However, the challenges are even more extensive when ethnic and geographic variations are taken into consideration.

Down syndrome is a rare but well-recognized disorder, with an estimated 250,000 people living with this disorder in the United States and an estimated 6000 new diagnoses made annually.<sup>3</sup> A 2002 study published in *Lancet* demonstrated that the mortality rate associated with this disorder is significantly greater in non-whites and that this marked racial disparity in survival begins early in infancy and persists

throughout childhood and into adulthood.<sup>4</sup> The authors further noted a median life expectancy that is two-times higher in whites compared with that in African-Americans and significantly higher than the racial disparity seen across the general U.S. population. Subsequent population-based studies further confirmed these striking health disparities among people with Down syndrome.<sup>5</sup> The underlying causes of these significant disparities remain unknown, but current data have suggested that it is likely not the result of comorbidities associated with the disorder.<sup>4</sup>

The All of Us Research Program, previously known as the Precision Medicine Initiative Cohort Program, was announced in 2015 and is currently being administered by the NIH in collaboration with an array of hospitals, academic institutions, and other health care partners.<sup>6</sup> The goal of this ambitious program is to collect health and genetic information from at least one million volunteers; enrollment officially began in May 2018. A major emphasis of the All of Us Research Program is to recruit individuals from diverse backgrounds because it is well recognized that racial, ethnic, geographic, and economic diversities are variables known to influence health outcomes and that individuals from diverse backgrounds continue to be underrepresented in discovery-type studies.<sup>7</sup>

Similarly, the U.S. Food and Drug Administration (FDA) encourages broadening the eligibility criteria in clinical trials to ensure the inclusion of diverse populations that are more representative of the patients who will likely use the drugs after their approval.<sup>8</sup> In June 2019, the FDA published a “draft guidance” entitled “Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs.”<sup>8</sup> The goal of these institutionalized initiatives is to provide a framework and the mechanisms to overtly account for diversity in the study and development of new therapeutics for commonly occurring diseases. Yet a persistent concern is how to reduce the recognized health disparities among those who live with rare diseases because it is unlikely that these large-scale initiatives will capture this population of patients.

To realize the full potential of precision medicine, Tabor and Goldenberg suggested that practitioners should think “small and rare and be proactive” to limit unexpected consequences.<sup>2</sup> Those invested in the study and care of patients with rare diseases have likely always

had to use this type of approach. Yet, when it comes to understanding the impact of diversity on health outcomes in this unique population of individuals, we may need to think big or at least bigger. As scientists and clinicians with a unique focus on rare diseases affecting the oral and maxillofacial complex, readers and contributors to *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology* are in a position to help shape the narrative and drive the discourse. Through the development of international collaborations, cases and resources can be pooled to gain greater insight than any single case or report might accomplish. Moreover, by being intentional about the inclusion of ethnic, geographic, and socioeconomic considerations, we can glean additional important insights that would inform future study designs and therapeutic approaches used for patients with rare diseases. It may also help further the intersection, if not eventually unify the goals and outcomes, of precision medicine and rare disease research and therapy.

*Faizan Alawi, DDS*  
*Section Editor, Oral Pathology*

<https://doi.org/10.1016/j.oooo.2019.11.016>

## REFERENCES

1. National Institutes of Health. What is precision medicine? Viewed 23 November 2019, Available at: <https://ghr.nlm.nih.gov/primer/precisionmedicine/definition>.
2. Tabor HK, Goldenberg A. What precision medicine can learn from rare genetic disease research and translation. *Am Med Assoc J Ethics*. 2018;20:E834-E840.
3. Lavigne J, Sharr C, Ozonoff A, et al. National Down syndrome patient database: insights from the development of a multi-center registry study. *Am J Med Genet A*. 2015;167 A:2520-2526.
4. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *Lancet*. 2002;359:1019-1025.
5. Kucik JE, Shin M, Siffel C, Marengo L, Correa A. Congenital anomaly multistate prevalence and survival collaborative. Trends in survival among children with Down syndrome in 10 regions of the United States. *Pediatrics*. 2013;131:e27-e36.
6. National Institutes of Health. All of Us Research Program. Viewed 23 November 2019, Available at: <https://allofus.nih.gov/>.
7. Crawford DC, Morgan AA, Denny JC, Aronow BJ, Brenner SE. Precision medicine: from diplotypes to disparities towards improved health and therapies. *Pac Symp Biocomput*. 2018;23:389-399.
8. United States Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry. Viewed 23 November 2019, Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial>.